ID: ALA357228

Max Phase: Preclinical

Molecular Formula: C16H23N3O10

Molecular Weight: 417.37

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(=O)NC[C@H]1O[C@@H](OC[C@H]2O[C@@H](n3ccc(=O)[nH]c3=O)[C@H](O)[C@@H]2O)[C@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C16H23N3O10/c1-6(20)17-4-7-10(22)13(25)15(29-7)27-5-8-11(23)12(24)14(28-8)19-3-2-9(21)18-16(19)26/h2-3,7-8,10-15,22-25H,4-5H2,1H3,(H,17,20)(H,18,21,26)/t7-,8-,10-,11-,12-,13-,14-,15-/m1/s1

Standard InChI Key:  ZELVGCWVJBOGJU-OUQNRHAVSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 417.37

Molecular Weight (Monoisotopic): 417.1383

AlogP: -4.24

#Rotatable Bonds: 6

Polar Surface Area: 192.57

Molecular Species: NEUTRAL

HBA: 11

HBD: 6

#RO5 Violations: 2

HBA (Lipinski): 13

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 9.70

CX Basic pKa:

CX LogP: -3.84

CX LogD: -3.85

Aromatic Rings: 1

Heavy Atoms: 29

QED Weighted: 0.26

Np Likeness Score: 1.13

References

1. Dini C, Drochon N, Feteanu S, Guillot JC, Peixoto C, Aszodi J..  (2001)  Synthesis of analogues of the O-beta-D-ribofuranosyl nucleoside moiety of liposidomycins. Part 1: contribution of the amino group and the uracil moiety upon the inhibition of MraY.,  11  (4): [PMID:11229763] [10.1016/s0960-894x(00)00715-0]

2. Patel B, Ryan P, Makwana V, Zunk M, Rudrawar S, Grant G..  (2019)  Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY.,  171  [PMID:30933853] [10.1016/j.ejmech.2019.01.071]

Source

Source(1):

• Scientific Literature